Drug-coated balloons for small coronary artery disease in patients with chronic kidney disease: a pre-specified analysis of the BASKET-SMALL 2 trial.
Drug-coated balloon
Renal insufficiency
Revascularization strategies
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
28
01
2022
accepted:
15
02
2022
pubmed:
28
2
2022
medline:
2
7
2022
entrez:
27
2
2022
Statut:
ppublish
Résumé
Data on the safety and efficacy of drug-coated balloon (DCB) compared to drug-eluting stent (DES) in patients with chronic kidney disease (CKD) are scarce, particularly at long term. This pre-specified analysis aimed to investigate the 3-year efficacy and safety of DCB versus DES for small coronary artery disease (< 3 mm) according to renal function at baseline. BASKET-SMALL-2 was a large multi-center, randomized, controlled trial that tested the efficacy and safety of DCBs (n = 382) against DESs (n = 376) in small vessel disease. CKD was defined as eGFR < 60 ml/min/1.73m A total of 174/758 (23%) patients had CKD, out of which 91 were randomized to DCB and 83 to DES implantation. The primary efficacy outcome during 3 years was similar in both, DCB and DES patients (HR 0.98; 95%-CI 0.67-1.44; p = 0.937) and patients with and without CKD (HR 1.18; 95%-CI 0.76-1.83; p = 0.462), respectively. Rates of cardiac death and all-cause death were significantly higher among patients with CKD but not affected by treatment with DCB or DES. Major bleeding events were lower in the DCB when compared to the DES group (12 vs. 3, HR 0.26; 95%-CI 0.07-0.92; p = 0.037) and not influenced by presence of CKD. The long-term efficacy and safety of DCB was similar in patients with and without CKD. The use of DCB was associated with significantly fewer major bleeding events (NCT01574534). Central Illustration. Drug-coated balloon versus drug-eluting stents in small coronary artery disease with and without chronic kidney disease, a prespecified subgroup analysis of the BASKET-SMALL 2 trial.
Sections du résumé
BACKGROUND
BACKGROUND
Data on the safety and efficacy of drug-coated balloon (DCB) compared to drug-eluting stent (DES) in patients with chronic kidney disease (CKD) are scarce, particularly at long term. This pre-specified analysis aimed to investigate the 3-year efficacy and safety of DCB versus DES for small coronary artery disease (< 3 mm) according to renal function at baseline.
METHODS
METHODS
BASKET-SMALL-2 was a large multi-center, randomized, controlled trial that tested the efficacy and safety of DCBs (n = 382) against DESs (n = 376) in small vessel disease. CKD was defined as eGFR < 60 ml/min/1.73m
RESULTS
RESULTS
A total of 174/758 (23%) patients had CKD, out of which 91 were randomized to DCB and 83 to DES implantation. The primary efficacy outcome during 3 years was similar in both, DCB and DES patients (HR 0.98; 95%-CI 0.67-1.44; p = 0.937) and patients with and without CKD (HR 1.18; 95%-CI 0.76-1.83; p = 0.462), respectively. Rates of cardiac death and all-cause death were significantly higher among patients with CKD but not affected by treatment with DCB or DES. Major bleeding events were lower in the DCB when compared to the DES group (12 vs. 3, HR 0.26; 95%-CI 0.07-0.92; p = 0.037) and not influenced by presence of CKD.
CONCLUSIONS
CONCLUSIONS
The long-term efficacy and safety of DCB was similar in patients with and without CKD. The use of DCB was associated with significantly fewer major bleeding events (NCT01574534). Central Illustration. Drug-coated balloon versus drug-eluting stents in small coronary artery disease with and without chronic kidney disease, a prespecified subgroup analysis of the BASKET-SMALL 2 trial.
Identifiants
pubmed: 35220449
doi: 10.1007/s00392-022-01995-3
pii: 10.1007/s00392-022-01995-3
pmc: PMC9242956
doi:
Substances chimiques
Coated Materials, Biocompatible
0
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
806-815Informations de copyright
© 2022. The Author(s).
Références
N Engl J Med. 2020 Apr 23;382(17):1608-1618
pubmed: 32227756
J Am Coll Cardiol. 2020 Mar 10;75(9):1061-1073
pubmed: 32138967
J Am Coll Cardiol. 2012 Dec 18;60(24):2473-80
pubmed: 23158530
J Am Coll Cardiol. 2016 Sep 6;68(10):1082-115
pubmed: 27036918
J Am Soc Nephrol. 2015 Oct;26(10):2504-11
pubmed: 25733525
Lancet. 2018 Sep 8;392(10150):849-856
pubmed: 30170854
J Am Coll Cardiol. 2020 Mar 10;75(9):1017-1028
pubmed: 32138961
Circulation. 2021 Mar 16;143(11):1157-1172
pubmed: 33720773
JACC Cardiovasc Interv. 2020 Jun 22;13(12):1391-1402
pubmed: 32473887
JACC Cardiovasc Interv. 2016 Oct 24;9(20):2097-2109
pubmed: 27692820
Am J Cardiol. 2015 Sep 1;116(5):686-93
pubmed: 26187674
Lancet. 2020 Nov 7;396(10261):1504-1510
pubmed: 33091360
Circulation. 2011 Jun 14;123(23):2736-47
pubmed: 21670242
J Am Coll Cardiol. 2012 Oct 16;60(16):1581-98
pubmed: 22958960
JACC Cardiovasc Interv. 2020 Apr 13;13(7):793-804
pubmed: 32061601
J Am Coll Cardiol. 2015 Sep 15;66(11):1209-1220
pubmed: 26361150
Clin Res Cardiol. 2020 Jul;109(7):845-856
pubmed: 31792571
J Am Coll Cardiol. 2018 Aug 14;72(7):754-765
pubmed: 30092952
Clin Cardiol. 2018 May;41(5):569-575
pubmed: 29527709
Eur Heart J. 2019 Jan 7;40(2):87-165
pubmed: 30165437
Circ Cardiovasc Interv. 2018 Mar;11(3):e006144
pubmed: 29870385
Eur Heart J. 2020 Oct 7;41(38):3715-3728
pubmed: 31511862
Circulation. 2007 May 1;115(17):2344-51
pubmed: 17470709